Hosted on MSN18m
AngioDynamics (ANGO) Reports Q2 Loss, Tops Revenue Estimates
AngioDynamics (ANGO) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.11. This compares to loss of $0.05 per share a year ago. These figures are ...
Hosted on MSN32m
BDSX Stock Rises After Publication of Study Data for Nodify CDT Test
Biodesix, Inc. BDSX recently announced a new post-market clinical validation study, published in CHEST Pulmonary Journal. The ...